Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults

Issels, Rolf D.; Abdel-Rahman, S.; Wendtner, Clemens-M.; Falk, M.; Kurze, Volker; Sauer, H.; Aydemir, Ülker; Hiddemann, Wolfgang

doi:10.1016/s0959-8049(01)00183-6

Cited by 126 publications

(65 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] Preoperative chemotherapy cannot be regarded as standard treatment to date; however, in 1996, available data justified the initiation of a European Organization for Research and Treatment of Cancer (EORTC) Phase III trial on neoadjuvant chemotherapy alone versus chemotherapy in conjunction with regional hyperthermia (RHT). 5,6 Today, RHT represents a standardized treatment option that usually is applied as an adjunct to radiotherapy and/or chemotherapy. In a number of Phase II and III trials, it has been shown that RHT improved local control in various locally advanced tumors.…”

Section: Resultsmentioning

confidence: 99%

Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia

Gellermann

Hildebrandt

Issels³

et al. 2006

Cancer

128

101

View full text Add to dashboard Cite

BACKGROUND The objective of this study was to evaluate noninvasive magnetic resonance (MR) thermography for the monitoring of regional hyperthermia (RHT) in patients with soft tissue sarcomas of the lower extremities and pelvis. METHODS Noninvasive MR monitoring during RHT was performed in 9 patients who had high‐risk soft tissue sarcomas of the lower extremities or pelvis during neoadjuvant chemotherapy plus RHT in the scope of the European Organization for Research and Treatment of Cancer 62961/European Society for Hyperthermic Oncology RHT‐95 study. Anatomic and temperature‐sensitive data sets were acquired every 10 minutes before and during RHT (using gradient‐echo‐sequences with variable echo times). MR temperature distributions were derived from the phase differences by using the proton‐resonance frequency shift method. A phase convolution setting phase shifts to zero in the fat tissue was performed as a drift correction. The mean MR temperatures in the tumor and muscles and the index temperatures (e.g., T90, which covers 90% of the target volume) and thermal doses were determined and compared with pathohistologic responses and direct temperature measurements if available. RESULTS Thirty of 72 MR‐thermography data sets (>40% of heat sessions) were evaluable. A significant correlation was observed between pathohistologic response (defined as a necrosis rate ≥90%) and standardized thermal parameters, such as thermal dose cumulative equivalent minutes at 43°C to 90% of the target volume (T90) (P = .050), mean T90 (P = .048), or T50 (P = .050). The correlation of 13 conventional temperature measurements performed in selected patients and sessions invasively in the tumor or noninvasively in rectum and bladder revealed an excellent correlation with MR temperatures (R2 = .96). CONCLUSIONS Noninvasive MR thermography of soft tissue sarcoma was feasible and suitable for validating the quality of heating during RHT. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%

Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia

Gellermann

Hildebrandt

Issels³

et al. 2006

Cancer

128

101

View full text Add to dashboard Cite

show abstract

“…Under mild temperature increases, clinical studies indicate an acceleration in both perfusion and reoxygenation [50,51] of tumor tissues, thereby increasing the efficacy of cytostatic drug delivery (chemosensitization) and radiotherapy (radiosensitization), respectively. In all cases, clinical studies indicate statistically significant benefits to local tumor control and overall survival rates for primary [40][41][42] and conjunctive hyperthermia [52][53][54][55][56]. Although promising, conventional non-invasive hyperthermic strategies are often less selective than those basedon or used in combination with thermal contrast agents, in many cases, causing damage to surrounding healthy tissues, as well as significant discomfort.…”

Section: Introductionmentioning

confidence: 99%

Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice

et al. 2008

View full text Add to dashboard Cite

Plasmonic photothermal therapy (PPTT) is a minimally-invasive oncological treatment strategy in which photon energy is selectively administered and converted into heat sufficient to induce cellular hyperthermia. The present work demonstrates the feasibility of in vivo PPTT treatment of deep-tissue malignancies using easily-prepared plasmonic gold nanorods and a small, portable, inexpensive near-infrared (NIR) laser. Dramatic size decreases in squamous cell carcinoma xenografts were observed for direct (P<0.0001) and intravenous (P<0.0008) administration of pegylated gold nanorods in nu/nu mice. Inhibition of average tumor growth for both delivery methods was observed over a 13-day period, with resorption of >57% of the directly-injected tumors and 25% of the intravenously-treated tumors.

show abstract

“…Patients included had tumors with size >5 cm, grade 2/3, deep with extracompartmental and recurrent sarcoma. Overall response rate was higher in hyperthermia group (28.7% versus 12.6%) with higher median PFS (45.3% versus 23.7%) [7].…”

Section: Neoadjuvant Chemotherapymentioning

confidence: 84%

Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Purohit

Bhise

Appachu

et al. 2011

Indian J Surg Oncol

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) comprise 1% of all cancers diagnosed worldwide with more than 40 different histological subtypes each with distinct underlying biology, natural history and response to treatment. Due to the differential chemosensitivity it is imperative to have a correct histological diagnosis for optimal treatment of these patients. Even though surgery remains the primary modality of treatment there is increasing specialization of chemotherapy with respect to histological subtype. In general there is no place for "one size fits all strategy". To correctly define the role of chemotherapy, an extensive search was carried out online and offline for all relevant articles concerning chemotherapy in soft tissue sarcoma. This review aims to discuss the evolution of chemotherapy, its present role in neoadjuvant, adjuvant, metastatic settings and exciting trends with the advent of targeted therapies.

show abstract

Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults

Cited by 126 publications

References 32 publications

Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia

Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia

Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice

Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Contact Info

Product

Resources

About